LEO launches chronic hand eczema drug in its first market Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE).

Knight Therapeutics Inc. GUD-T has signed a deal to buy the assets of Paladin Pharma Inc. as the Canadian drug company looks to build out its domestic business after a strategic push into South ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of ...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 ...

Activist Ryan Hampton sees a major flaw in the proposed $7.4 billion bankruptcy settlement reached by the OxyContin maker. While it's potentially one of the largest opioid settlements ever, he ...

US president Donald Trump has recently threatened to impose a 25% tariff on the EU, significantly escalating global trade tensions. Although these potential tariffs would impact the whole of the ...

A new survey commissioned by Leo Pharma confirms there’s plenty of room in the market for its chronic hand eczema treatment Anzupgo, which is currently under review by the FDA. The survey ...

The Frank post is one of several times Kingsley Wilson’s tweets have used the same language as antisemitic conspiracy theories. Kingsley Wilson, appointed in January to be deputy press ...

An Ipsos survey commissioned by LEO Pharma Inc. reveals dermatology providers believe there is a lack of awareness and understanding of chronic hand eczema as a condition separate from eczema ...

The news moves fast, but understanding takes time. At Vox, we don’t chase every headline. We focus on what really matters. We break down the biggest stories — and the ones others overlook ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. 2025 is going to be a big year for AI adoption in pharma. By now, most life science ...